In brief. To recruit a CEO for a biotech emerging from the era of its scientific founder, the board must settle three points before launching any search: the mandate entrusted to the future executive (commercialize, finance, sell, or pursue research), the founder's future role (director, shareholder, advisor, or full departure), and the transition timeline. In the public cases of 2026, between 107 and 146 days elapsed between the departure announcement and the naming of the successor, followed by three to six months before taking office.

On March 10, 2026, BioNTech announced that its two co-founders, Ugur Sahin and Özlem Türeci, would step down from their roles at the conclusion of their contracts to establish an independent company dedicated to next-generation messenger RNA. The supervisory board immediately launched a search to succeed them. On August 3, it announced the name of the future CEO: Guido Oelkers, hitherto CEO of Sobi, who will take office no later than February 1, 2027.

On the same day, Sobi announced that its CEO was leaving the company and that its board was immediately initiating the process to find a successor. One appointment triggers another, and what cost one party time, the other will in turn have to pay for.

In Basel, Idorsia experienced a shorter and bumpier sequence. On March 16, 2026, its CEO, Srishti Gupta, left the company by mutual agreement with the board after approximately nine months. The founder, Jean-Paul Clozel, resumed operational management. On July 1, the board appointed Roland Wandeler, formerly of Grifols, who has been in office since October 1.

These three cases do not tell the same story. Yet, they pose the same question to every board of directors, fund, and biotech founder: when a company transitions from discovery to execution, who should lead it, and how is the handover organized?

Key Figures

Why This Topic Matters Now

Three European biotech successions opened, played out, or concluded between March and October 2026, and they can be analyzed concurrently. BioNTech appointed its future CEO in August. Idorsia has had a new executive since October 1. Sobi has been searching for its own since August 3.

The French context makes the matter more pressing. According to the French HealthTech Panorama published by France Biotech on February 19, 2026, 41% of companies report cash-flow pressures and a funding round takes an average of ten months. A CEO arriving at a French biotech must therefore quickly secure funding, take the company public, or sell it. A founder's succession is not a human resources matter: it directly impacts the company's ability to raise its next round.

Three misconceptions circulate in these situations.

The founder must remain as long as they carry the science. This is often true for the scientific role, rarely for the CEO role. The two functions can be decoupled without the company losing out, provided it is formalized in writing.

Finding a big pharma name is enough. A biotech entering a commercial stage needs someone who knows how to make trade-offs with limited resources, under the watchful eye of investors.

The search begins when the founder leaves. BioNTech launched its search on the very day of the announcement. A succession that begins on the departure date is already behind schedule.

What a Founder's Departure Changes in a Biotech

In practice, a scientific founder combines four roles that company bylaws do not distinguish: they are the company's scientific authority, the figure of trust for investors, the magnet for researchers, and the guardian of culture. When they leave, these four roles do not depart together and cannot be replaced by a single person.

What disappears first is an authority that never needed justification. Trade-offs between programs and partnership decisions were made based on the weight of a name. A successor does not inherit that weight: they build their legitimacy through transparent decisions and a governance structure where roles are clearly delineated in writing.

What emerges is an imperative for execution. In BioNTech's case, the March press release indicates that the separation allows the company to focus on executing its late-stage pipeline, with approximately fifteen Phase 3 oncology trials expected by late 2026, while the new company takes over early-phase messenger RNA research. The future CEO himself set the course: transforming BioNTech into a global biopharmaceutical company with multiple approved products by 2030.

A successor's mandate is therefore primarily that of a transition phase: shifting from an operational model where the company is defined by its science to one where it is judged on its products, financing, and results.

Three Successions, Three Mandates

This reading is our own: press releases do not disclose the candidates boards set aside. It is based on what they chose to publish—namely, profiles of operators who have driven commercial growth in a biotech or biopharma division, rather than researcher-founder profiles.

In both public appointments, the board tied the choice to a specific phase. It is this alignment that makes the succession clear and credible to investors, teams, and partners.

Does the Founder Stay, and in What Capacity?

The most poorly framed question in a succession is the future role of the founder. It is often resolved by default under scheduling pressure, even though it dictates the successor's legitimacy.

Four configurations exist, and these public cases illustrate several of them.

1. Complete departure. The founder leaves the company, sometimes remaining a shareholder. The successor has full latitude, but the company loses its original scientific institutional memory.

2. The founder starts something new. This is the path BioNTech took: the two co-founders left to build a company dedicated to next-generation messenger RNA, to which BioNTech contributes technology and rights in exchange for a minority stake, milestones, and royalties. The separation is contractually organized, preventing role confusion.

3. The founder takes the helm during transition, then serves as chairman. This is Idorsia's path: Jean-Paul Clozel provided operational leadership from March to October, then remained board chairman according to RTTNews. Continuity is maintained, but the chairman must then refrain from making executive decisions in place of the CEO.

4. The founder as director or advisor. They retain a voice, risking the emergence of two conflicting sources of authority.

None of these configurations offers a one-size-fits-all answer. What matters is that it is defined in writing before the search, so the candidate knows whom they report to, and the team knows who has the final say.

The Domino Effect: One Appointment Launches Another Search

On August 3, 2026, two press releases were issued on the same day. One named the future CEO of BioNTech; the other announced the departure of Sobi's CEO. Sobi's board stated that it was immediately launching a search for his successor and that Mr. Oelkers would remain in office until the end of January 2027 at the latest.

This sequence illustrates three realities that boards often discover too late.

Notice periods are part of the timeline. Between BioNTech's appointment (August 3) and the executive taking office (no later than February 1, 2027), approximately six months elapse. A sitting executive at a publicly listed company cannot leave overnight, and their departure itself requires a structured transition.

Discretion is a prerequisite for the search. A sitting executive at a listed company puts their own position at risk by entertaining approaches. These approaches must be conducted before any public announcement.

The talent pool is finite. When a proven operator moves to another company, the same search opens at the firm they leave behind. For a board searching in the same segment, the sequence of appointments matters.

The French Context: A CEO Who Must Finance, List, or Sell

The French HealthTech Panorama 2026, published by France Biotech alongside Bpifrance, Euronext, EY, and Nextinnov/Banque Populaire, depicts an ecosystem of approximately 2,800 companies employing nearly 80,000 people. It describes a sector that is both dynamic and strained.

The funding figures for 2025 are mixed. French HealthTechs raised €2.3B, down 9%. Venture capital grew by 15% to €1.0B, while €1.3B came from public markets. The average market capitalization of listed companies reached €435M at the end of 2025, compared with €95M a year earlier. The 35 biotechs listed in Paris saw their market capitalization surge by 388%, an increase largely driven by a single company representing 62% of the sector's valuation.

This average masks a harsher reality: in 2025, only 20% of companies raised funds, compared to 37% in 2024. A funding round takes an average of ten months between initial contact and closing. 41% report cash-flow pressures, and 52% consider acquisition as their exit strategy.

This context sends a clear message to boards: the CEO of a French biotech cannot merely drive science. They must navigate a ten-month fundraising cycle, prepare for an IPO or sale, and make the company transparent and attractive to international investors.

What This Requires from Executive Roles

The Chief Financial Officer role warrants particular attention. Nanobiotix appointed a new CFO effective October 1, who previously served nearly five years in that role at a Nasdaq-listed biotech, following tenures at several European companies. This trend is not unique to that firm: in biotechs preparing for major financing, the CFO has become one of the most critical foundational hires alongside the CEO.

Five Decisions to Make Before Launching a Search

1. Define the phase. Discovery, clinical proof of concept, regulatory approval, commercial launch, or acquisition: each requires a different profile. A board that cannot define the phase it is entering in a single sentence cannot effectively evaluate a candidate.

2. Formalize the founder's role. Director, shareholder, scientific advisor, founder of a new venture, or full departure: choose one path, documented and signed by both the board and the founder.

3. Establish decision-making authority. Define what the future CEO decides independently, what must go to the board, and what stays under scientific governance.

4. Plan for the interim. Determine who leads during the search, for how long, and with what authority. Idorsia entrusted the interim leadership to its founder. Other companies assign interim duties to a CFO or an executive committee member. What matters is that the choice is deliberate.

5. Set the transition schedule. A start date six months out from appointment, as seen at BioNTech, requires a governance structure that can maintain stability during the interim.

Common Mistakes

Searching for a profile before defining the phase. A board looking for a "biotech CEO" without clarifying whether they are preparing for a launch, a sale, or a funding round will attract candidates misaligned with their actual needs.

Allowing the founder to pick their successor alone. They know the company better than anyone, but often evaluate profiles based on resemblance to themselves. The decision belongs to the board.

Confusing scientific prestige with leadership ability. Assessment must focus on managerial decisions the candidate has previously executed.

Underestimating the notice period. A candidate currently employed at a public company cannot start on the day of their appointment. BioNTech illustrates this: six months elapsed between naming the successor and taking office.

Overlooking the domino effect. Appointing an executive from a peer company triggers a search at that organization. Non-solicitation parameters and strict confidentiality must be anticipated from the outset.

How to Assess an Executive Succeeding a Biotech Founder

1. Have they previously led a company where the founder remained involved? Ask for specific examples of disagreements and how they were resolved. The answer reveals their ability to share authority without ceding it.

2. Which company stages have they managed, and with what outcomes? Whether a commercial launch, regulatory approval, fundraise, or acquisition: they must be able to describe a difficult decision made during that phase and what trade-offs were involved.

3. How do they describe the scientific pipeline they are inheriting? They should discuss prioritization choices with respect and clarity. A candidate who views science purely as a financial asset misunderstands the organization. One who treats it as sacrosanct will be unable to make tough trade-offs.

4. How do they interact with investors during high-stress periods? They should share the story of a difficult financing round, what they communicated to the market and their teams, and what they would do differently.

5. How do they plan to navigate the first 100 days? The right answer depends on the founder's role. They must articulate which decisions they will make independently, which they will share, and when they will report to the board.

Frequently Asked Questions

How do you recruit a biotech CEO?

You start by naming the phase the company is entering (commercialization, financing, exit), define the founder's future role in writing, and then conduct a direct, confidential search targeting sitting executives. The public cases of 2026 show a timeframe of 107 to 146 days between the departure announcement and the naming of a successor.

How long does it take to recruit a biotech CEO?

In the three 2026 cases, 107 days at Idorsia and 146 days at BioNTech elapsed between the departure announcement and the successor's naming. Notice periods must be factored in: 92 days at Idorsia, 182 days at BioNTech before officially taking office. This small sample serves as an illustration rather than a broad market statistic.

Can a scientific founder remain CEO of their biotech?

Yes, as long as the company's current phase aligns with their core strengths. When the company transitions to commercialization, international financing, or an exit, the board must consider whether the founder is best positioned for that stage and propose a formalized alternative role if they are not.

What profile should succeed a biotech founder?

It depends on the company's stage. Public appointments in 2026 favor leaders who have driven commercial growth in biopharma—such as a rare-disease company CEO who quadrupled revenue over nine years, or an executive from a large group's biopharma division.

Is an executive search firm necessary to recruit a biotech CEO?

It is not mandatory, but the search typically targets sitting executives—often at listed companies—who do not respond to job postings and whose recruitment requires utmost discretion. A healthcare-focused executive search firm manages this outreach confidentially while helping the board define the mandate.

What happens if a biotech CEO leaves without a successor?

The board appoints an interim leader. At Idorsia, the founder stepped back into operational management for more than three months. Any interim role must have a defined scope and timeline; otherwise, it becomes default governance.

Key Takeaways

• A biotech founder succession is decided by the mandate and the phase, not just the profile.

• Public cases in 2026 reveal 107 to 146 days between the departure announcement and naming a successor, followed by three to six months before taking office.

• The founder's future role must be codified in writing before launching the search.

• One appointment can trigger another search: the Sobi case illustrates the domino effect.

• In France, a biotech CEO must navigate an average ten-month fundraising timeline while preparing for an IPO or acquisition.

The Perspective of Laroze Partners

A founder succession is a governance decision before it is an executive search. Boards that treat it merely as a search for a profile realize too late that the real work lay elsewhere: articulating the company's next phase, codifying the founder's role, and setting the scope of the successor's independent authority. What makes the two 2026 appointments stand out is that each is clearly tied to a specific operational phase.

We advise shareholders, boards, and funds on these mandates across healthcare, pharma, biotech, and medical devices. Our work begins before the search by defining the mandate, and continues through post-placement integration. We make no judgment on the companies cited, which we do not know from the inside; we analyze what they have publicly shared.

The Laroze Pattern®, our methodology for strategically assessing career paths, leadership behaviors, and performance dynamics, identifies evidence in an executive's track record proving they have successfully navigated the targeted phase, rather than merely assuming it. Successful biotech handovers happen when organizations define their mandate before compiling a candidate list.

Sources

BioNTech press release, August 3, 2026 (appointment of Guido Oelkers) · BioNTech press release, March 10, 2026, reported by Bionity and BioPharm International (departure of co-founders, new company, successor search, Phase 3 trials) · Sobi press release, August 3, 2026, reported by Inderes (departure of Mr. Oelkers, 2025 revenue) · Bluewin, March 2026 (departure of Srishti Gupta at Idorsia) · RTTNews, July 1, 2026 (appointment of Roland Wandeler, board chairman) · France Biotech, French HealthTech Panorama 2026, February 19, 2026 (funding, employment, cash-flow pressures) · Nanobiotix, press release on the appointment of its CFO, in office October 1, 2026, reported by RTTNews.

Thomas Rozier is the founder of Laroze Partners, an executive search firm established in 2025 after more than a decade in executive recruiting, specializing in leadership appointments across healthcare, pharmaceuticals, biotechnology, and medical devices.